Early administration of propofol protects against endotoxin-induced acute lung injury in rats by inhibiting the TGF-β1-Smad2 dependent pathway
- First Online:
- Cite this article as:
- Gao, J., Zhao, WX., Xue, FS. et al. Inflamm. Res. (2010) 59: 491. doi:10.1007/s00011-009-0110-y
- 155 Downloads
To assess the effects of propofol treatments at different time points on acute lung injury and on the expression of transforming growth factor (TGF)-β1 and the downstream target of TGF-β1, Smad 2, in the lung tissues in the endotoxic rats.
Seventy-six Wistar rats were randomly assigned to five groups: control group (saline only), endotoxemic group [lipopolysaccharide (LPS) 8 mg kg−1, i.v.], and three propofol-treated groups. For the propofol-treated groups, propofol (5 mg kg−1, i.v. bolus) was administered either 1 h before LPS, simultaneously with LPS, and 1 h after LPS, and all were followed by infusion of 10 mg kg−1 h−1 of propofol for 5 h after LPS. Lung tissues were sampled to measure myeloperoxidase activity and expression of TGF-β1 and Smad2 and to assess pulmonary microvascular permeability and histopathological changes.
The hemodynamics, arterial blood gases, 5 h survival rate, pulmonary microvascular permeability, and acute lung injury scores were significantly better, and expression of TGF-β1 and Smad2 and myeloperoxidase activity in lung tissues was significantly lower in the pretreatment and simultaneous treatment groups compared to the endotoxemic group. However, there were no significant differences in all observed variables between the endotoxemic and postreatment groups. Except for TGF-β1 expression in lung tissues, the other observed variables were also not significantly different between the pretreatment and simultaneous treatment groups.
In the endotoxic rat model, pretreatment and simultaneous treatment with propofol provided protection against acute lung injury by inhibiting the TGF-β1-Smad2 dependent pathway.